A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study

A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study

A new lead compound has been designed as an antiangiogenic EGFR inhibitor that has the pharmacophoric characteristics to bind with the catalytic pocket of EGFR protein. The designed lead compound is a (para-chloro)acetamide derivative of the alkaloid, theobromine, (<b>T-1-PCPA</b>). At f...

Full description

Bibliographic Details
Main Authors: Ibrahim H. Eissa, Reda G. Yousef, Hazem Elkady, Aisha A. Alsfouk, Bshra A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Eslam B. Elkaeed, Ahmed M. Metwaly
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Life
Subjects:
EGFR inhibitor
semi synthesis
CADDD
DFT
docking
MD simulations
Online Access:https://www.mdpi.com/2075-1729/13/1/191

Internet

https://www.mdpi.com/2075-1729/13/1/191

Similar Items